FDA Drug Approvals
Printable Version   Email to a friend

Tygacil Wyeth Pharmaceuticals - Treatment for Complicated Skin and Intra-abdominal Infections

Tygacil is a glycylcycline antibiotic with a broad spectrum of antimicrobial activity, including activity against the drug-resistant bacteria methicillin-resistant Staphylococcus aureus (MRSA). Tygacil is indicated for the treatment of complicated intra- abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI) in adults.

Related Articles:

FDA Grants Tygacil (Tigecycline) NDA Priority Review Status - January 28, 2005

Wyeth Seeks Global Regulatory Approval of Tygacil (Tigecycline) for Injection - December 15, 2004

Latest FDA Drug Approvals...

FDA Drug Approvals Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Oct | Dec

More News Resources


MedNotes
Advertisement